|
BC incidence (‰ (95% CI))
|
5.7 (5.0–6.5)
|
3.7 (2.5–5.4)
|
5.1 (3.8–6.8)
|
5.4 (4.3–6.7)
|
9.1 (7.1–11.5)
|
< 0.001
|
|
BC cases
|
n = 216
|
n = 27
|
n = 48
|
n = 73
|
n = 68
| |
|
Only invasive BC incidence (‰ (95% CI))
|
4.4 (3.8–5.1)
|
3.5 (2.4–5.2)
|
3.7 (2.7–5.2)
|
3.6 (2.7–4.8)
|
7.5 (5.7–9.7)
|
< 0.001
|
|
Only invasive BC cases
|
n = 166
|
n = 26
|
n = 35
|
n = 49
|
n = 56
| |
|
Screened 1st round (N)
|
15,952
|
3109
|
3959
|
5727
|
3157
| |
|
Recall rate 1st round (% (95% CI))
|
13.4 (12.8–13.9)
|
9.2 (8.2–10.3)
|
12.9 (11.9–14.0)
|
14.7 (13.8–15.7)
|
15.6 (14.3–16.9)
|
< 0.001
|
|
Detection rate 1st round (‰ (95% CI))
|
7.1 (5.9–8.6)
|
6.4 (3.9–9.9)
|
7.1 (4.7–10.2)
|
6.6 (4.7–9.1)
|
8.9 (5.9–12.8)
|
0.624
|
|
Screen-detected 1st round
|
n = 114
|
n = 20
|
n = 28
|
n = 38
|
n = 28
| |
|
Interval cancer rate 1st round (‰ (95% CI))
|
2.5 (1.8–3.4)
|
0.6 (0.1–2.3)
|
1.3 (0.4–3.0)
|
1.9 (1.0–3.5)
|
7.0 (4.4–10.6)
|
< 0.001
|
|
Interval cancers
|
n = 40
|
n = 2
|
n = 5
|
n = 11
|
n = 22
| |
|
Interval cancers 0–12 months
|
n = 12
|
n = 1
|
n = 2
|
n = 1
|
n = 8
| |
|
Interval cancers 13 months or more
|
n = 28
|
n = 1
|
n = 3
|
n = 10
|
n = 14
| |
|
Screened 2nd round (N)
|
12,582
|
2509
|
3119
|
4522
|
2432
| |
|
Recall rate 2nd round (% (95% CI))
|
8.5 (8.0–9.0)
|
5.3 (4.5–6.3)
|
7.0 (6.1–7.9)
|
10.0 (9.1–10.9)
|
10.9 (9.7–12.2)
|
< 0.001
|
|
Detection rate 2nd round (‰ (95% CI))
|
4.9 (3.8–6.3)
|
2.0 (0.6–4.6)
|
4.8 (2.7–7.9)
|
5.3 (3.4–7.9)
|
7.4 (4.4–11.7)
|
0.055
|
|
Screen-detected 2nd round
|
n = 62
|
n = 5
|
n = 15
|
n = 24
|
n = 18
| |
